Reports Q4 revenue $24.78M, consensus $23.95M. “2025 was a milestone year for Ceribell (CBLL),” said co-founder and CEO Jane Chao. “We accelerated adoption across new and existing accounts, broadened the age range of our seizure detection algorithm to include pediatric and neonatal populations, and achieved critical regulatory milestones, unlocking incremental market opportunities that we believe exceed $1.5 billion. As we enter the new year, we believe these accomplishments position us well to drive continued growth and advance our long-term vision of making EEG a new vital sign.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- CBLL Earnings this Week: How Will it Perform?
- Ceribell: Strong Clinical Integration and AI-Driven Differentiation Support Buy Rating and High-Growth Outlook
- Ceribell: Expanding Neurology Platform, Growing TAM, and Attractive Valuation Support Buy Rating
- Ceribell: Breakthrough Stroke Detection and Expanding EEG Indications Underscore Attractive Multi‑Year Buy Opportunity
- Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool